Key Highlights
- Shares were down USD 0.2400, or 7.87%, at USD 2.81 in pre-market trading on November 4, 2026.
- The November 3, 2026 close was about USD 3.05, down about 1.3% on the day.
- A July 2026 private Placement raised about USD 275.0 million in gross proceeds.
- The second quarter 2026 net loss was USD 7.3 million, or USD 0.14 per share, against USD 2.7 million a year earlier.
- Cash and cash equivalents were USD 11.3 million at June 30, 2026, before the July placement.
What Moved Entera Bio Before the Open (down USD 0.2400, 7.87%)
Entera Bio Ltd. (NASDAQ:ENTX) was down 7.87% to USD 2.81 in pre-market trading on November 4, 2026, against the Tuesday, November 3, 2026 close of about USD 3.05.
No company press release or regulatory filing dated November 2 to November 4, 2026 was identified, so no catalyst was found. The company has not announced third quarter results, which market calendars estimate for about November 13, 2026 but which the company has not confirmed. A move without news in a stock that recently absorbed a very large financing may reflect positioning ahead of earnings.
The Latest Company Update in Detail
According to a company press release dated August 7, 2026, the FDA accepted a single placebo controlled Phase 3 design for EB613, an oral PTH(1-34) tablet for osteoporosis. The study is planned to enroll about 750 postmenopausal women, with the change in total hip bone mineral density at Month 12 as the primary endpoint, to support a New Drug Application. The company said the Phase 3 is planned to start in late 2026, with topline data expected in the second half of 2028.
The release also said single tablet data presented at ENDO 2026 showed profiles comparable to multi tablet EB613, and that a Phase 2 analysis was selected for a plenary poster at ASBMR 2026.
Business Background and Results
Entera Bio is a clinical stage biopharmaceutical company based in Jerusalem that develops orally delivered peptide therapies. Beyond EB613, it is developing EB612, an oral long acting PTH(1-34) for hypoparathyroidism with an IND filing planned with OPKO Health (NASDAQ:OPK) in the first half of 2027, and EB618 for obesity.
For the quarter ended June 30, 2026, Research and Development expenses were USD 3.2 million against USD 1.5 million a year earlier, and general and administrative expenses were USD 1.4 million against USD 1.1 million. Net financial expenses were USD 2.7 million, mostly a non-cash remeasurement of a USD 9.6 million pre-funded warrants liability, and the net loss was USD 7.3 million, or USD 0.14 per share.
Balance Sheet and Risks
Cash and cash equivalents were USD 11.3 million at June 30, 2026, compared with USD 7.1 million at December 31, 2025,. The company said the July 2026 private placement, which raised about USD 275.0 million gross and gave the lead investor the right to name two directors, should fund the EB613 Phase 3 through NDA submission and extend the cash runway into 2030.
Results are not expected until 2028. As a Penny Stock by price, it can show high volatility, uneven Liquidity and dilution risk from Warrant exercises.
What to Watch Next
The third quarter results, expected around mid November 2026, should show the cash position after the July placement and the pace of Phase 3 preparation. The start date of the EB613 Phase 3 trial, which the company has targeted for late 2026, is the main clinical milestone.






Please wait processing your request...